Cargando…

Aberrant expression of SPAG6 may affect the disease phenotype and serve as a tumor biomarker in BCR/ABL1-negative myeloproliferative neoplasms

Sperm-associated antigen 6 (SPAG6) is a newly identified cancer-testis antigen that has been revealed to contribute to the occurrence and development of various types of human cancer, such as ovarian, bladder, breast and lung cancer. However, to the best of our knowledge, the expression levels of SP...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ding, Li, Luo, Jie, Zhang, Jing Ping, Wang, Ji, Li, Zhao Quan, Huang, Juan, Chai, Li, Mu, Jiao, Zhao, Beibei, Zhong, Yi Rui, Zhang, Lin Yi, Liu, Lin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2022
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8607346/ https://www.ncbi.nlm.nih.gov/pubmed/34820009 http://dx.doi.org/10.3892/ol.2021.13128

Ejemplares similares

Upregulated SPAG6 correlates with increased STAT1 and is associated with reduced sensitivity of interferon‐α response in BCR::ABL1 negative myeloproliferative neoplasms
por: Ding, Li, et al.
Publicado: (2023)

Molecular approach to diagnose BCR/ABL negative chronic myeloproliferative neoplasms
por: Barcelos, Michelle Maccarini, et al.
Publicado: (2011)

Coexistence of JAK2 and BCR-ABL mutation in patient with myeloproliferative neoplasm
por: Hassan, Abdulaziz, et al.
Publicado: (2015)

GATA1 Expression in BCR/ABL1-negative Myeloproliferative Neoplasms
por: Yang, Naery, et al.
Publicado: (2018)

BCR::ABL1-negative myeloproliferative neoplasms in the era of next-generation sequencing
por: Mroczkowska-Bękarciak, Aleksandra, et al.
Publicado: (2023)

Kidney Involvement in Patients With Chronic Myelomonocytic Leukemia or BCR-ABL–Negative Myeloproliferative Neoplasms
por: Belliere, Julie, et al.
Publicado: (2020)

The immune landscape in BCR‐ABL negative myeloproliferative neoplasms: inflammation, infections and opportunities for immunotherapy
por: Strickland, Marie, et al.
Publicado: (2021)

Diagnosis- and Prognosis-Related Gene Alterations in BCR::ABL1-Negative Myeloproliferative Neoplasms
por: Morishita, Soji, et al.
Publicado: (2023)

Retrospective analysis of the clinical features of 172 patients with BCR-ABL1-negative chronic myeloproliferative neoplasms
por: Lin, Xiaolan, et al.
Publicado: (2020)

CCND2 mutations are infrequent events in BCR-ABL1 negative myeloproliferative neoplasm patients
por: Cassinat, Bruno, et al.
Publicado: (2020)

AXL Inhibition Represents a Novel Therapeutic Approach in BCR-ABL Negative Myeloproliferative Neoplasms
por: Beitzen-Heineke, Antonia, et al.
Publicado: (2021)

Synergic Crosstalk between Inflammation, Oxidative Stress, and Genomic Alterations in BCR–ABL-Negative Myeloproliferative Neoplasm
por: Allegra, Alessandro, et al.
Publicado: (2020)

Impact of Molecular Biology in Diagnosis, Prognosis, and Therapeutic Management of BCR::ABL1-Negative Myeloproliferative Neoplasm
por: Abbou, Norman, et al.
Publicado: (2022)

Recent advances in the bcr-abl negative chronic myeloproliferative diseases
por: Bennett, Michael, et al.
Publicado: (2006)

Insights from a rare myeloproliferative neoplasm with coexisting BCR‐ABL1 fusion gene, CALR, and TET2 mutations treated with nilotinib and ruxolitinib
por: Huo, Li, et al.
Publicado: (2023)

Allelic Expression Imbalance of JAK2 V617F Mutation in BCR-ABL Negative Myeloproliferative Neoplasms
por: Kim, Hye-Ran, et al.
Publicado: (2013)

Mutational Analysis of SH2B3 in Korean Patients With BCR-ABL1 Negative Myeloproliferative Neoplasm
por: Kim, Namhee, et al.
Publicado: (2016)

Chronic kidney disease in the BCR-ABL1-negative myeloproliferative neoplasm: a single-center retrospective study
por: Baek, Seung-Woo, et al.
Publicado: (2018)

Genetic Polymorphisms of Hemostatic Factors and Thrombotic Risk in Non BCR-ABL Myeloproliferative Neoplasms: A Pilot Study
por: Dambrauskienė, R, et al.
Publicado: (2017)

Mutation profile in BCR-ABL1-negative myeloproliferative neoplasms: A single-center experience from India
por: Maddali, Madhavi, et al.
Publicado: (2021)

Clinical and molecular profile of a Brazilian cohort of patients with classical BCR-ABL1-negative myeloproliferative neoplasms
por: Porto-Soares, Moysés Antonio, et al.
Publicado: (2020)

PB2187: ARTERIAL AND VENOUS THROMBOEMBOLIC COMPLICATIONS IN 832 PATIENTS WITH BCR-ABL-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS (MPN)
por: Wille, Kai, et al.
Publicado: (2023)

Anti-Interferon Alpha Antibodies in Patients with High-Risk BCR/ABL-Negative Myeloproliferative Neoplasms Treated with Recombinant Human Interferon-α
por: Aruna,, et al.
Publicado: (2018)

Atypical myeloproliferative neoplasm with concurrent BCR-ABL1 fusion and CALR mutation: A case report and literature review
por: Liu, Chunshui, et al.
Publicado: (2020)

Incidence, characteristics and risk factors of thromboembolic events in East Asian patients with BCR-ABL1 negative myeloproliferative neoplasms
por: Kim, Jinyong, et al.
Publicado: (2021)

Myelofibrosis-type megakaryocyte dysplasia (MTMD) as a distinct category of BCR::ABL-negative myeloproliferative neoplasms. Challenges and perspectives
por: Barosi, Giovanni, et al.
Publicado: (2023)

P1053: NEUTROPHIL-TO-LYMPHOCYTE AND PLATELET-TO-LYMPHOCYTE RATIO AS NOVEL PROGNOSTIC BIOMARKES IN BCR-ABL NEGATIVE MYELOPROLIFERATIVE NEOPLASMS
por: Cvetkovic, Mirjana, et al.
Publicado: (2023)

Imatinib and tyrosine kinase inhibition, in the management of BCR-ABL negative myeloproliferative disorders
por: Mesa, Ruben A
Publicado: (2007)

Mesenchymal stromal cells in tumor microenvironment remodeling of BCR-ABL negative myeloproliferative diseases
por: La Spina, Enrico, et al.
Publicado: (2023)

SOCS1 function in BCR-ABL mediated myeloproliferative disease is dependent on the cytokine environment
por: Demirel, Özlem, et al.
Publicado: (2017)

JAK2, CALR, and MPL Mutation Profiles in BCR-ABL Negative Myeloproliferative Neoplasms, a Referral Center Experience in the Middle East
por: Safavi, Moeinadin, et al.
Publicado: (2021)

The Prevalence of TET2 Gene Mutations in Patients with BCR-ABL-Negative Myeloproliferative Neoplasms (MPN): A Systematic Review and Meta-Analysis
por: Chia, Yuh Cai, et al.
Publicado: (2021)

PB2191: A RETROSPECTIVE MULTI-CENTER STUDY ON DIRECT ORAL ANTICOAGULANT USE IN BCR::ABL1 NEGATIVE MYELOPROLIFERATIVE NEOPLASMS
por: Baysal, Mehmet, et al.
Publicado: (2023)

Diagnostic Usefulness of the Janus Kinase 2 Mutation in non BCR/ABL Myeloproliferative Disorders
por: Bang, Soo-Mee, et al.
Publicado: (2006)

Risk-Reducing Genetic Variant of Wilms Tumor 1 Gene rs16754 in Korean Patients With BCR-ABL1-Negative Myeloproliferative Neoplasm
por: Kim, Namhee, et al.
Publicado: (2015)

Comparative study of different methodologies to detect the JAK2 V617F mutation in chronic BCR-ABL1 negative myeloproliferative neoplasms
por: Didone, Alline, et al.
Publicado: (2015)

Impact of diagnosis and treatment on response to COVID-19 vaccine in patients with BCR-ABL1-negative myeloproliferative neoplasms. A single-center experience
por: Cattaneo, Daniele, et al.
Publicado: (2021)

PB2234: EFFECT OF HYDROXYUREA ON INFLAMMATORY MARKERS IN PATIENTS WITH BCR-ABL NEGATIVE MYELOPROLIFERATIVE DISEASES
por: Altunok, Oguz, et al.
Publicado: (2023)

Aberrant expression of SPAG6 and NM23 predicts poor prognosis of human osteosarcoma
por: Bao, Zhengqi, et al.
Publicado: (2022)

Straightforward Identification of Masked Polycythemia Vera Based on Proposed Revision of World Health Organization Diagnostic Criteria for BCR-ABL1-Negative Myeloproliferative Neoplasms
por: Chu, Daehyun, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_s0ruoiai3d04gn4pb5q4bab0h4